Clinicopathological roles of adiponectin and leptin receptors in endometrial carcinoma.

Hiromitsu Yabushita, Keita Iwasaki, Yukihiko Obayashi, Akihiko Wakatsuki
Author Information
  1. Hiromitsu Yabushita: Department of Obstetrics and Gynecology, Aichi Medical University, School of Medicine, Nagakute, Aichi 480-1195, Japan.
  2. Keita Iwasaki: Department of Obstetrics and Gynecology, Aichi Medical University, School of Medicine, Nagakute, Aichi 480-1195, Japan.
  3. Yukihiko Obayashi: Department of Obstetrics and Gynecology, Aichi Medical University, School of Medicine, Nagakute, Aichi 480-1195, Japan.
  4. Akihiko Wakatsuki: Department of Obstetrics and Gynecology, Aichi Medical University, School of Medicine, Nagakute, Aichi 480-1195, Japan.

Abstract

To clarify the roles of adiponectin receptor (AdipoR) and leptin receptor (ObR) in endometrial carcinoma, the expression of AdipoR-1 and -2 and ObR.in endometrial cancer was examined immunohistochemically, and correlations with clinicopathological implications were also analysed. Paraffin-embedded tissues were obtained from 77 patients with endometrial carcinoma and were stained immunohistochemically using antibodies against AdipoR-1, AdipoR-2 and ObR. AdipoR-1, AdipoR-2 and ObR.were localised predominantly in the cell membrane and cytoplasm of tumour cells and normal endometrial cells. In 77 cases of endometrial cancer, positive expression was observed in 46 cases (59.7%) for AdipoR-1, 47 cases (61.0%) for AdipoR-2 and 33 cases (42.9%) for ObR. Expression of AdipoR-1 was observed most in stage I cases, G1 tumours, tumours with shallow myometrial invasion, tumours negative for lymphovascular space involvement, cases negative for adnexal invasion and cases with no lymph node metastasis. However, the expression of AdipoR-2 and ObR.showed no correlation with any clinicopathological factors. Kaplan-Meier analyses revealed that progression-free and overall survival times were longer in cases with positive AdipoR-1 expression compared with negative AdipoR-1 expression. Poor expression of AdipoR-1, thus, appears to be associated with tumour grade, myometrial invasion, adnexal invasion, lymph-vascular space involvement and lymph node metastasis, as well as poor prognosis, in endometrial cancer.

Keywords

References

  1. J Clin Endocrinol Metab. 2003 Mar;88(3):993-7 [PMID: 12629074]
  2. Gynecol Oncol. 2010 Oct;119(1):65-9 [PMID: 20674961]
  3. Endocrinology. 2006 Jul;147(7):3203-10 [PMID: 16601138]
  4. Eur J Gynaecol Oncol. 2008;29(6):594-7 [PMID: 19115685]
  5. Physiol Res. 2006;55(3):233-44 [PMID: 16238454]
  6. Endocr Relat Cancer. 2007 Sep;14(3):713-20 [PMID: 17914101]
  7. J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [PMID: 16288122]
  8. Cancer Res. 2008 Dec 1;68(23):9712-22 [PMID: 19047149]
  9. Cancer. 2006 Jun 1;106(11):2376-81 [PMID: 16639730]
  10. J Clin Endocrinol Metab. 2004 Mar;89(3):1102-7 [PMID: 15001594]
  11. Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81 [PMID: 14983034]
  12. FEBS Lett. 2004 Jan 30;558(1-3):27-32 [PMID: 14759511]
  13. Clin Cancer Res. 2004 Jul 1;10(13):4325-31 [PMID: 15240518]
  14. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):466-72 [PMID: 15701829]
  15. Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):74-7 [PMID: 17007993]
  16. Jpn J Clin Oncol. 2012 Feb;42(2):139-47 [PMID: 22172347]
  17. Histopathology. 2008 Oct;53(4):484-7 [PMID: 18983614]
  18. J Clin Endocrinol Metab. 2007 Jul;92(7):2665-71 [PMID: 17426091]
  19. Exp Cell Res. 2005 Sep 10;309(1):99-109 [PMID: 15963981]
  20. Obstet Gynecol. 1982 Jun;59(6):680-6 [PMID: 7078905]
  21. Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [PMID: 3652025]
  22. Int J Gynecol Pathol. 2012 Jul;31(4):352-7 [PMID: 22653349]
  23. Nature. 2003 Jun 12;423(6941):762-9 [PMID: 12802337]
  24. Urology. 2005 Jun;65(6):1168-72 [PMID: 15922427]
  25. J Cancer Res Clin Oncol. 2004 Nov;130(11):687-93 [PMID: 15322863]
  26. Mol Cancer Ther. 2011 Dec;10(12):2234-43 [PMID: 21980131]
  27. Endocr Rev. 2005 May;26(3):439-51 [PMID: 15897298]
  28. Biochem Biophys Res Commun. 2003 Dec 26;312(4):1118-22 [PMID: 14651988]
  29. J Clin Invest. 2006 Jul;116(7):1784-92 [PMID: 16823476]
  30. J Clin Endocrinol Metab. 2004 Mar;89(3):1160-3 [PMID: 15001602]
  31. Cytokine Growth Factor Rev. 2009 Jun;20(3):193-201 [PMID: 19520599]
  32. Cell Res. 2000 Jun;10(2):81-92 [PMID: 10896170]
  33. J Cell Physiol. 2006 Apr;207(1):12-22 [PMID: 16110483]
  34. Mol Cell Endocrinol. 2008 Mar 26;285(1-2):43-50 [PMID: 18313838]
  35. Gynecol Oncol. 1991 Jan;40(1):55-65 [PMID: 1989916]
  36. Br J Cancer. 2006 Jan 16;94(1):156-60 [PMID: 16404369]
  37. Int J Mol Med. 2000 Apr;5(4):421-6 [PMID: 10719061]
  38. Biochem Biophys Res Commun. 2012 Aug 31;425(3):560-4 [PMID: 22925674]
  39. Clin Cancer Res. 2006 Mar 1;12(5):1447-53 [PMID: 16533767]
  40. J Natl Cancer Inst. 2002 Nov 20;94(22):1704-11 [PMID: 12441326]
  41. Cancer Lett. 2007 Jun 8;250(2):229-36 [PMID: 17123704]
  42. Nature. 1994 Dec 1;372(6505):425-32 [PMID: 7984236]
  43. Adv Med Sci. 2009;54(2):150-7 [PMID: 19875356]
  44. Am J Obstet Gynecol. 1985 Apr 15;151(8):1009-15 [PMID: 3985062]
  45. Br J Cancer. 2006 May 8;94(9):1221-5 [PMID: 16570048]
  46. Cancer Sci. 2007 Jul;98(7):1120-7 [PMID: 17459059]
  47. J Clin Endocrinol Metab. 2007 Jan;92(1):255-63 [PMID: 17062769]

Word Cloud

Created with Highcharts 10.0.0endometrialAdipoR-1casesObRexpressionreceptorcarcinomaAdipoR-2invasionadiponectinleptincancertumoursnegativerolesimmunohistochemicallyclinicopathological77tumourcellspositiveobservedmyometrialspaceinvolvementadnexallymphnodemetastasisclarifyAdipoR-2examinedcorrelationsimplicationsalsoanalysedParaffin-embeddedtissuesobtainedpatientsstainedusingantibodieslocalisedpredominantlycellmembranecytoplasmnormal46597%47610%33429%ExpressionstageG1shallowlymphovascularHowevershowedcorrelationfactorsKaplan-Meieranalysesrevealedprogression-freeoverallsurvivaltimeslongercomparedPoorthusappearsassociatedgradelymph-vascularwellpoorprognosisClinicopathologicalreceptorsimmunohistochemistry

Similar Articles

Cited By (4)